Xiangyu MedicalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Xiangyu MedicalLtd şirketinin toplam hissedar öz sermayesi CN¥2.0B ve toplam borcu CN¥330.0M olup, bu da borç-öz sermaye oranını 16.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.8B ve CN¥760.8M dir. Xiangyu MedicalLtd 'in FAVÖK'ü CN¥83.8M faiz karşılama oranı -8.1 dur. Şirketin CN¥732.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

16.2%

Borç/özkaynak oranı

CN¥329.99m

Borç

Faiz karşılama oranı	-8.1x
Nakit	CN¥732.04m
Eşitlik	CN¥2.04b
Toplam yükümlülükler	CN¥760.83m
Toplam varlıklar	CN¥2.80b

Son finansal sağlık güncellemeleri

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Jul 04

Recent updates

Why Xiangyu MedicalLtd's (SHSE:688626) Soft Earnings Are Just The Beginning Of Its Problems

Nov 06

Further Upside For Xiangyu Medical Co.,Ltd (SHSE:688626) Shares Could Introduce Price Risks After 41% Bounce

Oct 09

Xiangyu Medical Co.,Ltd (SHSE:688626) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 24

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Jul 04

Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions

Apr 24

CN¥50.78: That's What Analysts Think Xiangyu Medical Co.,Ltd (SHSE:688626) Is Worth After Its Latest Results

Apr 21

Capital Allocation Trends At Xiangyu MedicalLtd (SHSE:688626) Aren't Ideal

Apr 18

Pinning Down Xiangyu Medical Co.,Ltd's (SHSE:688626) P/E Is Difficult Right Now

Mar 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 688626 'nin kısa vadeli varlıkları ( CN¥1.1B ) kısa vadeli yükümlülüklerini ( CN¥624.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 688626 şirketinin kısa vadeli varlıkları ( CN¥1.1B ) uzun vadeli yükümlülüklerini ( CN¥136.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 688626 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 688626 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 16.2% seviyesine yükseldi.

Borç Kapsamı: 688626 'nin borcu işletme nakit akışı ( 46% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 688626 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Xiangyu MedicalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Recent updates

Why Xiangyu MedicalLtd's (SHSE:688626) Soft Earnings Are Just The Beginning Of Its Problems

Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.46 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Further Upside For Xiangyu Medical Co.,Ltd (SHSE:688626) Shares Could Introduce Price Risks After 41% Bounce

New minor risk - Share price stability

Xiangyu Medical Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 16% to CN¥40.78

Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.44 in 2Q 2023)

Xiangyu Medical Co.,Ltd (SHSE:688626) Looks Inexpensive But Perhaps Not Attractive Enough

Xiangyu MedicalLtd (SHSE:688626) Seems To Use Debt Quite Sensibly

Xiangyu Medical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

Xiangyu MedicalLtd's (SHSE:688626) Performance Raises Some Questions

CN¥50.78: That's What Analysts Think Xiangyu Medical Co.,Ltd (SHSE:688626) Is Worth After Its Latest Results

Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2024

Capital Allocation Trends At Xiangyu MedicalLtd (SHSE:688626) Aren't Ideal

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1Q 2023)

Xiangyu Medical Co.,Ltd to Report Q1, 2024 Results on Apr 18, 2024

Pinning Down Xiangyu Medical Co.,Ltd's (SHSE:688626) P/E Is Difficult Right Now

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 15%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 15%

Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.33 in 3Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.19 in 2Q 2022)

Xiangyu Medical Co.,Ltd to Report First Half, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.06 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.28 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.40 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares.

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin